Previous 10 | Next 10 |
Image source: The Motley Fool. Seer, Inc. (NASDAQ: SEER) Q1 2022 Earnings Call May 04, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Seer, Inc. (SEER) Q1 2022 Earnings Call Transcript
Seer press release (NASDAQ:SEER): Q1 GAAP EPS of -$0.38 in-line. Revenue of $3.31M (+5416.7% Y/Y) beats by $0.58M. The company continues to expect FY2022 revenue to be in the range of $14M to $16M, and, as previously disclosed, the company also expects to continue to increase investments in i...
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2022. “We had a strong start to the year as w...
Gainers: Redbox Entertainment (RDBX) +48%. Blue Apron Holdings (APRN) +36%. Accolade (ACCD) +28%. Forge Global Holdings (FRGE) +22%. Hilltop Holdings (HTH) +19%. The Oncology Institute (TOI) +18%. OppFi (OPFI) +18%. Seer (SEER) +16%. Companhia Energetica de Minas Gerais (CIG) +16%. Silk Road ...
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vega...
Gainers: AlloVir (ALVR) +41%. Biophytis (BPTS) +22%. Clarus Therapeutics (CRXT) +22%. Healthcare Services (HCSG) +20%. BioSig Technologies (BSGM) +6%. Losers: Arcturus Therapeutics (ARCT) -22%. Diffusion Pharmaceuticals (DFFN) -13%. Seer (SEER) -7%. HTG Molecular...
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter of 2022 on Wednesday, May 4, 2022. Company management w...
Seer (NASDAQ:SEER) appointed Scott D. Thomas as chief commercial officer effective Mar. 21. Thomas joins SEER from Singular Genomics, where he served as SVP, sales and marketing. For further details see: Seer hires Scott Thomas as chief commercial officer
REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins See...
Published results highlight simultaneous superior performance across depth, precision, and throughput versus conventional plasma proteomics workflows REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced the publication of...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company manag...
Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation Creation of first-of-its-kind comprehensive atlas of molecular and physiological multiomic profiles available from multiple spaceflight missions REDWOOD CIT...
REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to da...